MEDS

DataMeds AI, Inc. MEDS

NasdaqSmall CapConsumer Staples

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $23.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.78M

Quarter to Jun 30

Net income

$-18.36M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$160.6K total
JANE STREET GROUP, LLC
$63.6K-78.2%
GEODE CAPITAL MANAGEMENT, LLC
$38.6K-98.2%
VANGUARD CAPITAL MANAGEMENT LLC
$34.4K-98.2%
VANGUARD FIDUCIARY TRUST CO
$19.2K-98.0%
BARCLAYS PLC
$2.2KNew
Tower Research Capital LLC (TRC)
$2.1KNew
Fortitude Family Office, LLC
$366New
Integrated Wealth Concepts LLC
$78New
Global Retirement Partners, LLC
$6--
DANSKE BANK A/S
$3New
See all 10 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MEDS

Earnings Per Share

13fpro.ai/company/MEDS

Loading ratio trend…

MEDS key financials by period

Reported revenue, net income and operating margin by fiscal year, from DataMeds AI, Inc.'s annual filings on SEC EDGAR.

DataMeds AI, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$23.3M$-101.3M—
FY 2024$18.1M$-6.9M-33.9%
Source: MEDS filings on SEC EDGAR →

MEDS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About DataMeds AI, Inc. (MEDS): stock profile, AI score and financials

DataMeds AI, Inc. (MEDS) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. MEDS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $23.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), DataMeds AI, Inc. reports quarterly revenue of $1.8M, net income of $-18.4M. Top institutional holders of MEDS by reported 13-F value include JANE STREET GROUP, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MEDS trades on the Nasdaq exchange and files with the SEC under CIK 2030763. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MEDS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DataMeds AI, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 2030763 →